EDUCATION AND POSITIONS HELD:

• B.S., School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2003)
• Ph.D., Department and Graduate Institute of Pharmacology , College of Medicine, National Taiwan University, Taipei, Taiwan (2012)
• Postdoctoral Training, College of Medicine, National Taiwan University, Taipei Taiwan (2012-2013)
• Postdoctoral Training, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2013-2014)
• Assistant Professor, PhD Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2014-2018)
• Associate Professor, PhD Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2018-2021)
• Associate Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2021-2023)
• Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2023-Present)
• Joint-Appointment Professor, Graduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2023-Present)
• Joint-Appointment Professor, PhD Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2023-Present)
• Joint-Appointment Professor, Master Program in Clinical Genomics and Proteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2023-Present)
• Joint-Appointment Professor, PhD Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2023-Present)
• Member, TMU Research Center of Drug Discovery
• Member, TMU Research Center of Thoracic Medicine 
• The Chair of the Department of Pharmaceutical Sciences, School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan (2024-present)

Cancer pharmacology encompasses a wide range of therapeutic issues. In the early stages of new drug discovery, translational research has refined the identification of therapeutic targets for clinical relevance and applications. As our understanding of tumor molecular characteristics expands, it becomes more feasible to find existing drugs for drug repurposing or design new drugs that align with these specific characteristics for cancer treatment.

Our training program intends to provide trainees with knowledge of cancer pharmacology, cancer biology, and required lab skills (cell culture, cell viability assays for drug screening, western blotting, flow cytometry analysis, immunofluorescence microscopy analysis) for the understanding of preclinical drug discovery for cancer therapy. We are looking for students who are motivated, ambitious, collaborative, and are interested in doing research with us.

RESEARCH INTERESTS:

As tumor cells tend to escape from apoptosis by upregulating survival signaling or loss of tumor suppressor genes, induction of cell death by novel small molecules or herbal medicine initiates cellular networks and leads to anticancer activity. We are interested in investigating different type of cancer cell death, autophagy, post-translational modifications, cancer metabolism, and DNA damage signaling pathways in cancer cells. Currently, we are particular interested in research new therapeutic targets in pediatric high-grade gliomas (pHGGs) and FGFR3-TACC3 fusion bladder cancers with different approaches to improve the selective cytotoxicity of the drugs used in cancer therapy.